Recent Appointments at Roche in Palo Alto

Palo Alto, Calif., May 6, 2002 -- The Roche research & development operations, Roche Bioscience in Palo Alto, announced the following appointments:

• Paul Cannon, Ph.D., has been appointed vice president and head of the central nervous system therapy area in the Neurobiology Business Unit. In this position he heads a group of employees focused primarily on the discovery of new medicines to treat psychiatric disorders such as anxiety, depression and schizophrenia. Cannon reports to Ian Massey, senior vice president and head of Neurobiology. Cannon was previously vice president of core sciences.
• Tony Manning, Ph.D., has joined Roche as vice president of arthritis and osteoporosis in the Inflammatory and Viral Diseases Unit. Manning will be responsible for all drug discovery in the arthritis and osteoporosis therapy areas. Manning joins Roche from Pharmacia Corp. in St. Louis, Mo., where he was vice president, arthritis and inflammatory diseases discovery research. He reports to Robert Booth, senior vice-president and head Inflammatory and Viral Diseases Unit.
• Dennis Romley has joined Roche as senior vice president of human resources. Romley joins Roche from Threshold Consulting in Portola Valley, a business he started to assist companies through workplace transitions. Prior to that he was vice president of staff operations for SRI Consulting, a subsidiary of SRI International. Romley is a member of the Roche Bioscience operating committee and reports to James N. Woody, Ph.D., president, Roche Bioscience.

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world’s premier research-based healthcare groups. With leading businesses in pharmaceuticals, diagnostics and vitamins, Roche offers a uniquely broad range of products and services that span prevention, diagnosis and treatment, thus enhancing health, well being and quality of life. Roche invests nearly 4 billion Swiss francs, or about $2.4 billion, annually in research and development. Its research focuses on significant unmet medical needs in the management of diseases of the central nervous system and genitourinary tract, metabolic disorders, inflammation, bone diseases, cancer, vascular diseases and virology. Roche employs approximately 7,000 people in research and development and has five global pharmaceutical research centers located in Basel, Switzerland; Kamakura, Japan; Penzburg, Germany; Nutley, N.J., and Palo Alto, Calif.

The Roche Bioscience research center in Palo Alto, Calif., focuses on the discovery and early clinical development of innovative medicines to treat diseases in the following areas: arthritis, asthma and other respiratory diseases; anxiety, depression, schizophrenia and other neuropsychiatric diseases; genitourinary diseases, osteoporosis, HIV/AIDS, and hepatitis C.

Following are URL's for Roche on the web:

Global website: www.roche.com.

U.S. pharmaceuticals business: www.rochusa.com.

Roche Bioscience: http://paloalto.roche.com.

###